---
title: "Key facts: Abbott completes TECTONIC IVL; closes Exact; raises guidance"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/292999283.md"
description: "Abbott completed TECTONIC IVL trial enrollment, gained CE Mark for Libre Duo, and submitted Amulet 360 to the FDA. It closed its acquisition of Exact Sciences, integrating sales into Cancer Diagnostics. Abbott raised full-year adjusted EPS guidance and maintained sales growth forecasts at 6.5–7.5%, driven by strong diagnostics and diabetes care performance, despite a 3.1% year-over-year decline in nutrition sales."
datetime: "2026-07-17T07:14:12.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/292999283.md)
  - [en](https://longbridge.com/en/news/292999283.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/292999283.md)
---

# Key facts: Abbott completes TECTONIC IVL; closes Exact; raises guidance

-   Abbott (ABT) completed U.S. enrollment for the TECTONIC IVL trial, presented late-breaking PFA/CSP data, gained CE Mark for Libre Duo, and submitted Amulet 360 to the FDA. 1
-   Abbott Laboratories closed Exact Sciences deal on March 23, 2026. Exact’s sales now sit in Abbott’s Cancer Diagnostics segment and are included in the segment’s comparable‑sales reporting. 2
-   Abbott (ABT) kept full-year sales growth at 6.5–7.5% and raised adjusted EPS guidance, citing stronger diagnostics and diabetes care performance that boosted outlook. 3
-   Abbott (ABT) Q2 2026 nutrition sales fell 3.1% YoY (comp sales -3.6%). US pediatric sales down 10.7%, international pediatric up 7.3%. Nutrition sales rose $127M sequentially. 4

### Related Stocks

- [ABT.US](https://longbridge.com/en/quote/ABT.US.md)
- [EXAS.US](https://longbridge.com/en/quote/EXAS.US.md)

## Related News & Research

- [23:20 ETPRIVACY ALERT: Abbott Laboratories and Exact Sciences Corporation Under Investigation for Data Breach of Patient Records](https://longbridge.com/en/news/293695963.md)
- [Abbott wins dismissal of shareholder lawsuit over 2022 infant formula recall](https://longbridge.com/en/news/293792909.md)
- [Abbott investigates two separate cyber incidents, says no operations affected](https://longbridge.com/en/news/293079773.md)
- [These Analysts Increase Their Forecasts On Abbott Following Better-Than-Expected Q2 Results](https://longbridge.com/en/news/293046426.md)
- [ABT: Q2 2026 delivered strong sales and EPS growth, with raised guidance and innovation milestones](https://longbridge.com/en/news/292931675.md)